Downregulation of the Paired Box Gene 3 Inhibits the Progression of Skin Cutaneous Melanoma by Inhibiting C-MET Tyrosine Kinase : PAX3 Downregulation Inhibits Melanoma Progression

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2022 Sep 4

PMID 36057879

Authors

Kun Zhang

Chunfang Yu

Ruoxi Tian

Wancong Zhang

Shijie Tang

Guiying Wang

Affiliations

Soon will be listed here.

Abstract

Background: The PAX3 (paired box gene 3) gene is highly expressed in several cancer types. However, its underlying mechanism of action in skin cutaneous melanoma (SKCM) remains unknown.

Methods: In this study, we used the GEPIA database and western blotting to analyze the expression of PAX3. We performed the Kaplan-Meier survival analysis to evaluate the prognostic value of PAX3 in SKCM. Next, the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was performed to evaluate the function of PAX3-related co-expressed genes. Additionally, the function and potential mechanism of action of PAX3 in SKCM were studied through functional experiments. Western blotting was used to detect the changes in the levels of epithelial-mesenchymal transition (EMT)-related and MET (c-MET tyrosine kinase) proteins following PAX3 knockdown. Finally, we assessed the correlation between PAX3 expression and the infiltration of CD4/CD8 T cells using the TISIDB database.

Results: We found that PAX3 was overexpressed in the SKCM tissues and that these levels were indicative of a poor prognosis of SKCM. The KEGG pathway enrichment analysis showed that PAX3-related co-expressed genes were mainly associated with the oncogenic pathways. Knocking down PAX3 significantly inhibited the proliferation, invasion, and migration of SK-MEL-28 cells. The PAX3 expression was related significantly to the immune infiltration level of CD4/CD8 T cells.

Conclusions: Our findings demonstrated that PAX3 knockdown could reverse the EMT of tumor cells, inhibit the growth, and progression of SKCM cells. Therefore, PAX3 may have implications as a potential therapeutic target and promising prognostic biomarker for SKCM.

Citing Articles

Numb and NumbL inhibit melanoma tumor growth by influencing the immune microenvironment.

Zhang S, Zang L, Li Y, Pang Y, Xin Y, Zhang Y BMC Cancer. 2024; 24(1):1419.

PMID: 39558287 PMC: 11571900. DOI: 10.1186/s12885-024-13191-9.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Hamid O, Robert C, Daud A, Hodi F, Hwu W, Kefford R . Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019; 30(4):582-588. PMC: 6503622. DOI: 10.1093/annonc/mdz011. View

Tremblay P, Gruss P . Pax: genes for mice and men. Pharmacol Ther. 1994; 61(1-2):205-26. DOI: 10.1016/0163-7258(94)90063-9. View

Baldwin C, Hoth C, Macina R, Milunsky A . Mutations in PAX3 that cause Waardenburg syndrome type I: ten new mutations and review of the literature. Am J Med Genet. 1995; 58(2):115-22. DOI: 10.1002/ajmg.1320580205. View

Rajan P, Panchision D, Newell L, McKay R . BMPs signal alternately through a SMAD or FRAP-STAT pathway to regulate fate choice in CNS stem cells. J Cell Biol. 2003; 161(5):911-21. PMC: 2172962. DOI: 10.1083/jcb.200211021. View

Wu M, Li J, Engleka K, Zhou B, Lu M, Plotkin J . Persistent expression of Pax3 in the neural crest causes cleft palate and defective osteogenesis in mice. J Clin Invest. 2008; 118(6):2076-87. PMC: 2381747. DOI: 10.1172/JCI33715. View

Wang Q, Fang W, Krupinski J, Kumar S, Slevin M, Kumar P . Pax genes in embryogenesis and oncogenesis. J Cell Mol Med. 2008; 12(6A):2281-94. PMC: 4514106. DOI: 10.1111/j.1582-4934.2008.00427.x. View

Mascarenhas J, Littlejohn E, Wolsky R, Young K, Nelson M, Salgia R . PAX3 and SOX10 activate MET receptor expression in melanoma. Pigment Cell Melanoma Res. 2010; 23(2):225-37. PMC: 2979310. DOI: 10.1111/j.1755-148X.2010.00667.x. View

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

10.

Vasaikar S, Straub P, Wang J, Zhang B . LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2017; 46(D1):D956-D963. PMC: 5753188. DOI: 10.1093/nar/gkx1090. View

11.

Ru B, Wong C, Tong Y, Zhong J, Zhong S, Wu W . TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019; 35(20):4200-4202. DOI: 10.1093/bioinformatics/btz210. View

12.

Chen M, Zhang L, Liu X, Ma Z, Lv L . PER1 Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Ovarian Cancer. Front Genet. 2021; 12:697471. PMC: 8248530. DOI: 10.3389/fgene.2021.697471. View

13.

Zhang K, Tian R, Wang G, Zhang J, Ma H, Hu X . ADAMTS8 Inhibits Cell Proliferation and Invasion, and Induces Apoptosis in Breast Cancer. Onco Targets Ther. 2020; 13:8373-8382. PMC: 7457586. DOI: 10.2147/OTT.S248085. View

14.

Stanton S, Disis M . Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016; 4:59. PMC: 5067916. DOI: 10.1186/s40425-016-0165-6. View

15.

Clark Jr W, Elder D, Guerry 4th D, Braitman L, Trock B, Schultz D . Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989; 81(24):1893-904. DOI: 10.1093/jnci/81.24.1893. View

16.

WAARDENBURG P . A new syndrome combining developmental anomalies of the eyelids, eyebrows and nose root with pigmentary defects of the iris and head hair and with congenital deafness. Am J Hum Genet. 1951; 3(3):195-253. PMC: 1716407. View

17.

Soukup S, Ballard E, Gotwals B, Lampkin B . Chromosomal analysis of sixteen human rhabdomyosarcomas. Cancer Res. 1988; 48(4):983-7. View

19.

Gryder B, Yohe M, Chou H, Zhang X, Marques J, Wachtel M . PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. Cancer Discov. 2017; 7(8):884-899. PMC: 7802885. DOI: 10.1158/2159-8290.CD-16-1297. View

21.

Tonelli R, McIntyre A, Camerin C, Walters Z, Di Leo K, Selfe J . Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy. Clin Cancer Res. 2011; 18(3):796-807. DOI: 10.1158/1078-0432.CCR-11-1981. View

22.

Pandey P, Chatterjee B, Olanich M, Khan J, Miettinen M, Hewitt S . PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma. J Pathol. 2017; 241(5):626-637. PMC: 5357165. DOI: 10.1002/path.4867. View